Lamictal in the Treatment of Post-Herpetic Neuralgia

NCT00295776 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2013-03-13

No results posted yet for this study

Summary

To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.

Conditions

  • Neuralgia, Postherpetic

Interventions

DRUG

Lamictal in the treatment of Post-Herpetic Neuralgia

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY
  • George Washington University

    lead OTHER

Principal Investigators

  • Perry K. Richardson, M.D. · The George Washington University Medical Faculty Associates

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00295776 on ClinicalTrials.gov